pi3k/akt/mtor
jak/stat（janus激酶/信号转导子和转录激活子）信号通路将来自细胞外的化学信号传递给细胞核，导致与免疫、增殖、分化、凋亡和肿瘤发生等相关基因的dna转录和表达。此信号通路是众多细胞因子信号转导的共同途径，其活性在炎性疾病和血液恶性肿瘤等疾病治疗研究中具有重要意义。jak-stat信号级联由三个主要成分组成：由*激酶相关受体、*激酶jak和转录因子stat三个成分组成。
jak/stat通路转导过程
细胞因子，如干扰素、白细胞介素和生长因子等配体，与细胞表面受体结合，引起受体分子二聚化。与受体偶联的jak相互接近并通过交互的*磷酸化而被激活。活化后的jak使受体的*磷酸化，为具有sh2结构域的stat创建结合位点。stat结合至受体后，在jak作用下，stat*705（tyr 705）被磷酸化。stat就会从受体上脱离，形成同/异二聚体。stat二聚体进入细胞核后，会结合特定的调节序列以激活或抑制靶基因的转录。
jak/stat信号通路图
产品列表
按靶点分类：
*jak
项目号产品名称规格cas包装细胞靶点ic50ki
r126338 ruxolitinib (incb018424) ≥98% 941678-49-5 5mg,25mg,50mg,100mg 无细胞 jak1 3.3 nm
jak2 2.8 nm
e129454 tofacitinib (cp-690550) citrate ≥99% 540737-29-9 10mg,50mg,250mg jak1 112 nm
jak2 20 nm
jak3 1 nm
a126326 azd1480 ≥98% 935666-88-9 5mg,25mg,100mg 无细胞 jak2 0.26 nm
t126330 fedratinib (sar302503, tg101348) ≥98% 936091-26-8 5mg,25mg,100mg 无细胞 jak2 3 nm
j126663 janex-1 98% 202475-60-3 5mg,10mg,50mg jak3 78 μm
w125855 whi-p97 ≥98% 211555-05-4 10mg,50mg jak-3 0.09 μm
c127224 cyt387 ≥98% 1056634-68-4 5mg,10mg,50mg,100mg jak1 11 nm
jak2 18 nm
t122330 tofacitinib ≥98% (hplc) 477600-75-2 5mg,25mg,100mg,500mg,1g 无细胞 jak3 1 nm
w129459 wp1066 ≥98% 857064-38-1 10mg,50mg hel细胞 jak2 2.30 μm
stat3 2.43 μm
t127523 tg101209 98% 936091-14-4 5mg,25mg,100mg 无细胞 jak2 6 nm
flt3 25 nm
ret 17 nm
l126490 ly2784544 ≥98% 1229236-86-5 5mg,10mg,50mg jak2 3 nm
n129609 nvp-bsk805 2hcl ≥97% 1092499-93-8 5mg,10mg,50mg jak2 0.5 nm
b127687 baricitinib ≥99% 1187594-09-7 5mg,10mg,50mg 无细胞 jak1 5.9 nm
jak2 5.7 nm
a129464 az 960 ≥99% 905586-69-8 2mg,5mg,10mg jak2 ＜3 nm ＜0.45 nm
c129474 cep-33779 ≥99% 1257704-57-6 5mg,10mg,50mg jak2 1.8 nm
w125072 whi-p154 ≥98% 211555-04-3 10mg,50mg jak3 1.8 μm
x127151 xl019 ≥99% 945755-56-6 5mg,25mg jak2 2.2 nm
s129613 s-ruxolitinib (incb018424) ≥99% 941685-37-6 5mg,10mg,50mg jak1 3.3 nm
jak2 2.8 nm
z129618 zm 39923 hcl ≥98% 1021868-92-7 10mg,50mg,250mg jak1 4.4
jak3 7.1
r171967 ruxolitinib phosphate salt 97% 1092939-17-7 100mg jak
c114054 莪术醇 分析标准品,≥98% 4871-97-0 20mg
*stat
项目号产品名称规格cas包装细胞靶点ic50
s129625 s3i-201 ≥99% 501919-59-1 5mg,10mg,50mg stat3 86 μm
f122998 氟达拉滨 98% 21679-14-1 50mg,250mg,1g,5g stat1
s129623 stattic ≥98% 19983-44-9 25mg,100mg stat3 5.1 μm
n130841 * 98% 50-65-7 50g,250g 无细胞 stat3 0.7 μm
n114456 * 分析标准品 50-65-7 100mg 无细胞 stat3 0.7 μm
n129550 nifuroxazide ≥98% 965-52-6 50mg,100mg stat1/3/5 3 µm
a107818 * 98% 88495-63-0 5g,25g 小细胞肺癌细胞系h69 stat3 < 5 μm
c101974 隐丹参酮 98% 35825-57-1 50mg,250mg 无细胞 stat3 4.6 μm
c101973 隐丹参酮 分析标准品,≥98% 35825-57-1 20mg 无细胞 stat3 4.6 μm
*egfr
项目号产品名称规格cas包装细胞靶点ic50ki
e129310 erlotinib hcl (osi-744) ≥99% 183319-69-9 100mg,500mg,1g,5g 无细胞 egfr 2 nm
g125799 gefitinib (zd1839) ≥99% 184475-35-2 50mg,250mg,1g,5g,25g,100g nr6wtegfr和nr6w细胞 tyr1173 37 nm
tyr992 37nm
tyr1173 26 nm
tyr992 57 nm
l129338 二对甲苯磺酸拉帕替尼(gw-572016) ≥98% 388082-77-7 25mg,100mg,250mg,500mg,1g 无细胞 egfr 10.8 nm
erbb2 9.2 nm
a129323 afatinib ≥99% 439081-18-2 5mg,10mg,50mg 无细胞 egfr(wt) 0.5 nm
egfr(l858r) 0.4 nm
egfr(l858r/t790m) 10 nm
erbb2（her2） 14 nm
erbb4（her4） 1 nm
n126132 neratinib (hki-272) ≥99% 698387-09-6 5mg,25mg,100mg 无细胞 her2 59 nm
egfr 92 nm
p125741 pd153035 ≥98% 153436-54-5 10mg,50mg,250mg egfr 5.2 pm
t162509 *激酶抑制剂 ag 494 >98.0%(hplc)(n) 133550-35-3 20mg,100mg egfr 1.2 μm
egf 6 μm
c125447 canertinib (ci-1033) ≥98% 267243-28-7 10mg,50mg,250mg egfr 1.5 nm
erbb2 9.0 nm
l126696 lapatinib ≥99% 231277-92-2 25mg,100mg,250mg,500mg,1g,5g 无细胞 egfr 10.2 nm
erbb2 9.8 nm
a126525 ag-490 (tyrphostin b42) ≥98% 133550-30-8 20mg,50mg,250mg,1g 无细胞 egfr 0.1 μm
c129397 cp-724714 ≥99% 537705-08-1 5mg,10mg,25mg,50mg her2/erbb2 10 nm
d129347 dacomitinib (pf299804, pf299) ≥99% 1110813-31-4 5mg,10mg,50mg,250mg 无细胞 egfr 6 nm
w127713 wz4002 ≥98% 1213269-23-8 10mg,50mg,100mg baf3细胞系 egfr(l858r) 2 nm
egfr(t790m) 8 nm
a129380 azd8931 (sapitinib) ≥98% 848942-61-0 5mg,10mg,50mg egfr 4 nm
erbb2 3 nm
erbb3 4 nm
c127191 cudc-101 ≥98% 1012054-59-9 10mg,25mg,50mg,100mg,250mg hdac 4.4 nm
egfr 2.4 nm
her2 15.7 nm
a126582 ag-1478 (tyrphostin ag-1478) ≥98% 153436-53-4 5mg,10mg,25mg,50mg 无细胞 egfr 3 nm
p129384 pd153035 hcl ≥98%(hplc) 183322-45-4 10mg,50mg,250mg egfr 29 pm 5.2 pm
p125444 pelitinib ≥98% 257933-82-7 5mg,25mg,100mg egfr 38.5 nm
b126145 ac480 (bms-599626) ≥98% 714971-09-2 5mg,25mg,100mg her1 20 nm
her2 30 nm
a126830 aee788 (nvp-aee788) ≥97% 497839-62-0 5mg,25mg,100mg egfr 2 nm
her2/erbb2 6 nm
a127691 ap26113 ≥98% 1197958-12-5 5mg,10mg,25mg,50mg,100mg alk
egfr
o125033 osi-420 ≥99% 183320-51-6 5mg,10mg,50mg egfr 2 nm
w127717 wz3146 ≥98% 1214265-56-1 5mg,25mg,100mg egfr(l858r) 2 nm
egfr(e746_a750) 2 nm
a126334 arry-380 ≥98% 937265-83-3 5mg,10mg,50mg her2 8 nm
w126471 wz8040 ≥98% 1214265-57-2 5mg,25mg,50mg egfrt790m
a129426 ast-1306 tsoh ≥98% 1050500-29-2 5mg,10mg,50mg egfr 0.5 nm
erbb2 3 nm
c124905 co-1686 (avl-301) ≥99% 1374640-70-6 5mg,10mg,50mg,100mg 无细胞 egfrl858r/t790m 21.5 nm
egfrwt 303.3 nm
g106672 金雀异黄酮 分析标准品,≥98% 446-72-0 20mg,1g,5g nih-3t3细胞 egf 12μm
胰岛素 19 μm
g106673 金雀异黄酮 97% 446-72-0 100mg,500mg,1g,5g,25g nih-3t3细胞 egf 12μm
胰岛素 19 μm
v129433 varlitinib ≥96% 845272-21-1 5mg,10mg,50mg erbb1(egfr) 7 nm
erbb2(her2) 2 nm
i129405 icotinib ≥99% 610798-31-7 5mg,10mg,50mg egfr 5 nm
t126234 tak-285 ≥98% 871026-44-7 5mg,10mg,50mg her2和egfr(her1) 17 nm
her2和egfr(her1) 23 nm
w125072 whi-p154 ≥98% 211555-04-3 10mg,50mg jak3 1.8 μm
d155111 daphnetin >90.0%(hplc) 486-35-1 50mg,250mg,1g egfr 7.67 μm
pka 9.33 μm
pkc 25.01 μm
p129447 pd168393 ≥98% 194423-15-9 10mg,50mg,250mg egfr 0.70 nm
t129439 tyrphostin 9 ≥98% 10537-47-0 25mg,100mg,500mg egfr 460 μm
pdgfr 0.5μm
t129445 tyrphostin 23 ≥98% 118409-57-7 10mg,50mg,250mg egfr 35 μm
o173511 olmutinib 97% 1353550-13-6 100mg egfr
e107403 (-)-表没食子儿茶素没食子酸酯 分析标准品 989-51-5 20mg,100mg,500mg
e107404 (-)-表没食子儿茶素没食子酸 98% 989-51-5 100mg,500mg,2.5g
e126633 erlotinib ≥98% 183321-74-6 100mg,500mg,1g,5g egfr 2 nm
n159736 norcantharidin 98% 29745-04-8 1g,5g,25g c-met
egfr
b135922 butein ≥98.0%(hplc) 487-52-5 100mg,1g
*pim
项目号产品名称规格cas包装细胞靶点ic50
s126376 sgi-1776 free base ≥98% 1025065-69-3 5mg,10mg,50mg 无细胞 pim1 7 nm
t125988 smi-4a ≥98% 438190-29-5 10mg,50mg pim1 17 nm
a127698 azd1208 ≥98% 1204144-28-4 5mg,25mg,100mg pim1 0.4 nm
pim2 5 nm
pim3 1.9 nm